decisionhealth Newsletters, Part B News - 2002 Issue 8 (August)
How to bill for Zevalin
Subscribe or sign in to view the full article.
Article Overview
This article covers CMS guidance on billing for Zevalin, a radioactive therapy used in a specific non-Hodgkin’s lymphoma setting. It discusses the related diagnostic and therapeutic components, the coding and payment framework referenced in a CMS program memo, and the fact that CMS was considering a national coverage policy. The article is relevant to coders, billing staff, oncology practices, nuclear medicine teams, and compliance professionals who need to understand how the CMS guidance was framed at the time.
Why This Topic Matters
This matters because coverage and billing rules for specialty therapies can change quickly, and CMS policy direction can affect whether services are payable and how claims are reported. Understanding the article helps readers identify the service categories and agency guidance involved without needing to rely on outdated assumptions.
What You Will Learn
- The CMS coverage context surrounding Zevalin billing guidance
- The general split between diagnostic and therapeutic components of the service
- Which types of organizations and agencies are referenced in the billing guidance
- How CMS framed the possibility of a national coverage policy for the therapy
Who Should Read This
- Medical coders
- Billing specialists
- Oncology practice administrators
- Nuclear medicine staff
- Compliance professionals
- Revenue cycle teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com